

# XI Myeloma workshop - preliminary program October 12-13, 2016

#### Day 1

9:00 registration opened

9:15 R. Hajek (Czech Republic) - Introduction

### **AMYLOIDOSIS**

 $9:30\ G.$  Merlini (Italy) - Systemic amyloidoses: from disease mechanisms to novel therapies

10:30 A. Wechalekar (Great Britain) - An update on systemic AL amyloidosis

 $11:15\ \mathrm{T.}$  Pika (Czech Republic) - Diagnosis and treatment of senile systemic amyloidosis - single centre experience

11:30 D. Holub (Czech Republic) - Subtyping of amyloid deposits by mass spectrometry-based proteomic analysis

 $11{:}45\ \mathsf{T.}$  Sevcikova (Czech Republic) - Sample processing for high throughput techniques: methodological approach

12:00 - 13:30 lunch

## EXTRAMEDULLARY RELAPSE

13:30 L. Rihova (Czech Republic) - Identification of phenotype profile related to the extramedullary involvement in myeloma relapses

13:50 S. Sevcikova (Czech Republic) – Extramedullary relapse of multiple myeloma- data from Brno

14:10 C. Fernández de Larrea (Spain) - Clinical features and response to treatment of patients with multiple myeloma and extramedullary involvement

14:30 A. Jurczyszyn (Poland) - Skin and CNS involvement in MM

15:00 - 15:30 coffee break

## HOT TOPICS

15:30 D. Hofste op Bruinink (the Netherlands) - The genomic landscape of multiple myeloma with a deletion of chromosome 17p: biallelic, nonsilent aberrations in TP53 are

common and negatively affect survival

15:50 L. Besse (Switzerland) - Proteasome inhibitor resistance of multiple myeloma can

be overcome by Nelfinavir, an approved HIV drug
16:10 T. Jelinek (Czech Republic) - Immune checkpoint inhibitors in multiple myeloma.

19:00 dinner

# Day 2 FLOW CYTOMETRY WORKSHOP

10:30 informal coffee break

11:00 Theoretical part

11.00 Theoretical part

L. Rihova (Brno) - What is new in MRD assessment in MM P. Vsianska (Brno) - Analysis of MRD in EMNO2 study

R. Bezdekova (Brno) - MRD assessment using Duraclone PC tubes

V. Kanderova (CLIP Prague) - Phosphoflow - new trend in clinical flow cytometry
D. Hofste op Bruinink (the Netherlands) - Flowcytometric Minimal Residual Disease

Assessment in the EMN-02/HOVON-95 MM Trial: Used Methods and a Comparison of Their Sensitivity

12:00 lunch

13:00 practical part - Hands on Infinicyt SW (notebook and mouse needed!)





